The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 53
- Locations
- 1
- Primary Endpoint
- Apnea-Hypopnea Index
Study Overview
Brief Summary
Obstructive sleep apnea and hypertension are well-known cardiovascular risk factors. Their control could reduce the burden of heart disease across populations. There are several drugs to control hypertension, but the only consistently beneficial treatment to reduce apneas is continuous positive airway pressure. The demonstration that one drug could improve sleep apnea and hypertension would support a novel approach in the treatment of both diseases. The role of fluid retention in sleep apnea is known for several decades. The role of diuretics is well established in hypertension but was never appropriately tested in sleep apnea. Besides to test the efficacy of these drugs, this study will help to understand the mechanisms that link hypertension and sleep apnea and its treatment.
Detailed Description
This is a randomized, double-blind, clinical trial, comparing the association of Chlorthalidone plus amiloride 25 and 5 mg daily, versus amlodipine 10 mg daily as first drug option in patients older than 40 years of age with Stage I hypertension (140-159/90-99 mmHg) and moderate obstructive sleep apnea (15-30 apneas/hour of sleep). The primary outcomes will be the variation of apneas/hour and blood pressure. The secondary outcomes will be adverse events, somnolence scale (Epworth), ventilatory parameters and C reactive protein. The follow up will last 8 weeks. The sample size will be of 29 participants per group. The project was approved by the Ethics committee of our institution.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients older than 40 years of age
- •Stage I hypertension (140-159/90-99 mmHg) and moderate obstructive sleep apnea (10-40 apneas/hour of sleep)
Exclusion Criteria
- •Low life expectancy
- •Other indications for the use of diuretics or calcium channel blocker -Intolerance or contraindications to the study drugs
- •Pregnancy
- •Established cardiovascular disease (myocardial infarction
- •Heart failure)
- •Use of more than one drug for hypertension
- •Secondary hypertension
- •Participation in other clinical trial in previous 6 months
Arms & Interventions
Diuretics
Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
Intervention: Diuretics (Drug)
Calcium Channel Blockers
Amlodipine 10 mg daily, taking in the morning
Intervention: Calcium Channel Blockers (Drug)
Outcomes
Primary Outcomes
Apnea-Hypopnea Index
Time Frame: 8 weeks
Number of apneas/hour
Blood Pressure
Time Frame: 8 weeks
Secondary Outcomes
- Adverse events(8 weeks)
- Somnolence scale (Epworth) and ventilatory parameters(8 weeks)
- C reactive protein(8 weeks)